Erik Verner

4.4k total citations · 1 hit paper
30 papers, 2.5k citations indexed

About

Erik Verner is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Erik Verner has authored 30 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 11 papers in Genetics and 8 papers in Oncology. Recurrent topics in Erik Verner's work include Blood Coagulation and Thrombosis Mechanisms (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Protease and Inhibitor Mechanisms (5 papers). Erik Verner is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Protease and Inhibitor Mechanisms (5 papers). Erik Verner collaborates with scholars based in United States, China and Australia. Erik Verner's co-authors include Joseph J. Buggy, Mint Sirisawad, Sriram Balasubramanian, Richard A. Miller, Douglas H. Thamm, Lee Honigberg, Ashley M. Smith, Betty Chang, Zhengying Pan and David Loury and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Erik Verner

29 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

2010 1.2k citations Mint Sirisawad, Erik Verner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Verner United States	18	1.3k	899	593	545	474	30	2.5k
Zhengying Pan China	21	1.3k 1.0×	1.4k 1.6×	840 1.4×	702 1.3×	476 1.0×	42	3.0k
Mint Sirisawad United States	17	1.3k 1.0×	956 1.1×	767 1.3×	695 1.3×	230 0.5×	38	2.4k
Judy Lucas United States	34	2.2k 1.7×	480 0.5×	287 0.5×	1000 1.8×	1.1k 2.2×	69	4.1k
Steven W. Elmore United States	24	3.2k 2.4×	470 0.5×	425 0.7×	1.2k 2.2×	716 1.5×	37	4.8k
Brian E. Schultz United States	18	881 0.7×	422 0.5×	266 0.4×	379 0.7×	268 0.6×	33	1.8k
Paul Nimmer United States	8	1.8k 1.4×	274 0.3×	221 0.4×	665 1.2×	222 0.5×	11	2.4k
Kumudha Balakrishnan United States	26	1.2k 0.9×	1.5k 1.7×	893 1.5×	484 0.9×	213 0.4×	52	2.8k
William C. Shakespeare United States	29	1.8k 1.3×	461 0.5×	192 0.3×	933 1.7×	816 1.7×	59	3.2k
Pingda Ren United States	21	2.3k 1.7×	307 0.3×	176 0.3×	570 1.0×	636 1.3×	49	3.2k
Juerg Schwaller Switzerland	33	2.1k 1.6×	569 0.6×	844 1.4×	1.2k 2.2×	300 0.6×	66	3.8k

Countries citing papers authored by Erik Verner

Since Specialization

Citations

This map shows the geographic impact of Erik Verner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Verner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Verner more than expected).

Fields of papers citing papers by Erik Verner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Verner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Verner. The network helps show where Erik Verner may publish in the future.

Co-authorship network of co-authors of Erik Verner

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Verner. A scholar is included among the top collaborators of Erik Verner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Verner. Erik Verner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenbaum, James T., Erik Verner, William B. Jones, et al.. (2024). Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity. 1(1). 3 indexed citations

Janc, James W., Craig Hill, Patrick P. Ng, et al.. (2019). Abstract 1313: CPI-818: A selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) that inhibits T-cell receptor signaling, promotes Th1 skewing, and achieves objective tumor responses when administered to dogs with T cell lymphomas. Cancer Research. 79(13_Supplement). 1313–1313. 3 indexed citations

Venetsanakos, Eleni, Ken A. Brameld, Vernon T. Phan, et al.. (2017). The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance. Molecular Cancer Therapeutics. 16(12). 2668–2676. 22 indexed citations

Brameld, Ken A., Timothy D. Owens, Erik Verner, et al.. (2017). Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry. 60(15). 6516–6527. 84 indexed citations

Zhong, Yiming, Shuai Dong, Ethan Strattan, et al.. (2015). Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. Journal of Biological Chemistry. 290(10). 5960–5978. 37 indexed citations

Balasubramanian, Sriram, Erik Verner, & Joseph J. Buggy. (2009). Isoform-specific histone deacetylase inhibitors: The next step?. Cancer Letters. 280(2). 211–221. 174 indexed citations

Balasubramanian, Sriram, Jason Ramos, Weigang Luo, et al.. (2008). A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 22(5). 1026–1034. 363 indexed citations

Cao, Zhe, Kathryn E. Bass, Sriram Balasubramanian, et al.. (2006). CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Molecular Cancer Therapeutics. 5(7). 1693–1701. 25 indexed citations

Young, Wendy B., Paul A. Sprengeler, William D. Shrader, et al.. (2005). Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation. Bioorganic & Medicinal Chemistry Letters. 16(3). 710–713. 9 indexed citations

10.

Katz, B.A., Christine Luong, Joseph D. Ho, et al.. (2004). Dissecting and Designing Inhibitor Selectivity Determinants at the S1 Site Using an Artificial Ala190 Protease (Ala190 uPA). Journal of Molecular Biology. 344(2). 527–547. 29 indexed citations

11.

Katz, B.A., Kyle Elrod, Erik Verner, et al.. (2003). Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-directed Serine Protease Inhibitors. Journal of Molecular Biology. 329(1). 93–120. 30 indexed citations

12.

Mackman, Richard L., Hon C. Hui, J. Guy Breitenbucher, et al.. (2002). 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors. Bioorganic & Medicinal Chemistry Letters. 12(15). 2019–2022. 27 indexed citations

13.

Katz, B.A., Paul A. Sprengeler, Christine Luong, et al.. (2001). Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chemistry & Biology. 8(11). 1107–1121. 51 indexed citations

14.

Katz, B.A., Kyle Elrod, Christine Luong, et al.. (2001). A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site11Edited by D. Rees. Journal of Molecular Biology. 307(5). 1451–1486. 61 indexed citations

15.

Rai, Roopa, Aleksandr Kolesnikov, Yong Li, et al.. (2001). Development of potent and selective factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters. 11(14). 1797–1800. 7 indexed citations

16.

Verner, Erik, B.A. Katz, Jeffrey R. Spencer, et al.. (2001). Development of Serine Protease Inhibitors Displaying a Multicentered Short (<2.3 Å) Hydrogen Bond Binding Mode: Inhibitors of Urokinase-Type Plasminogen Activator and Factor Xa. Journal of Medicinal Chemistry. 44(17). 2753–2771. 111 indexed citations

17.

Chan, Ming Fai, Erik Verner, B. Raju, et al.. (1998). The discovery and structure—activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ETB receptor. Bioorganic & Medicinal Chemistry. 6(12). 2301–2316. 23 indexed citations

18.

Verner, Erik & Theodore Cohen. (1992). Inversion of configuration in the displacement of lithium by hydrogen during a transannular 1,4-hydrogen transfer accompanying a [1,2]-Wittig rearrangement. The Journal of Organic Chemistry. 57(4). 1072–1073. 17 indexed citations

19.

Verner, Erik & Theodore Cohen. (1992). Stereochemical analysis of totally stereoselective competing [1,2]- and 2,3]-Wittig rearrangements. Inversion at the lithium-bearing carbon atom. Journal of the American Chemical Society. 114(1). 375–377. 67 indexed citations

20.

Natale, Nicholas R., et al.. (1990). The Use of Phosphonitrilic Dichloride Cyclic Trimer in Oligopeptide Synthesis. Synthesis of Isoxazolyl-Prodrugs of Netropsin and Distamycin. Heterocycles. 31(2). 327–327. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact